[{"orgOrder":0,"company":"Lemonex Bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Lemonex Announces IND Approval for Phase 1 Clinical Trial of LEM-S401, siRNA Gene Therapeutics With Nano-Drug Delivery Platform DegradaBALL\u00ae","therapeuticArea":"Dermatology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2022","year":"2022","type":"Not Applicable","leadProduct":"LEM-S401","moa":"","url1":"","url2":"","graph1":"Dermatology","graph2":"IND Enabling","graph3":"Lemonex Bio","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Lemonex Bio \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Lemonex Bi.."},{"orgOrder":0,"company":"Lemonex Bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Lemonex, mRNA-DegradaBALL Vaccine LEM-mR203 Clinical Phase 1 Trial IND Submission","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"February 2023","year":"2023","type":"Not Applicable","leadProduct":"LEM-mR203","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"IND Enabling","graph3":"Lemonex Bio","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Lemonex Bio \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Lemonex Bi.."},{"orgOrder":0,"company":"Lemonex Bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Lemonex Announces Approval of IND Application for mRNA-DegradaBALL Vaccine, LEM-mR203, Phase 1 Clinical Trial","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"August 2023","year":"2023","type":"Not Applicable","leadProduct":"LEM-mR203","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"IND Enabling","graph3":"Lemonex Bio","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Lemonex Bio \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Lemonex Bi.."}]

Find Clinical Drug Pipeline Developments & Deals by Lemonex Bio

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          BioProcess International
                          Not Confirmed
                          BioProcess International
                          Not Confirmed

                          Details : LEM-mR203 is the first mRNA vaccine candidate to which Lemonex's proprietary drug delivery platform technology, DegradaBALL (DegradaBALL-mRNA system), is applied, investigating for the treatment of Covid-...

                          Brand Name : LEM-mR203

                          Molecule Type : Vaccine

                          Upfront Cash : Not Applicable

                          August 09, 2023

                          Lead Product(s) : LEM-mR203

                          Therapeutic Area : Infections and Infectious Diseases

                          Highest Development Status : IND Enabling

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank

                          02

                          BioProcess International
                          Not Confirmed
                          BioProcess International
                          Not Confirmed

                          Details : LEM-mR203 is a safer and more efficient mRNA vaccine candidate by applying DegradaBALL® technology that can complement the limitations of LNP. It is being investigated as a booster shot for Covid-19.

                          Brand Name : LEM-mR203

                          Molecule Type : Vaccine

                          Upfront Cash : Not Applicable

                          February 14, 2023

                          Lead Product(s) : LEM-mR203

                          Therapeutic Area : Infections and Infectious Diseases

                          Highest Development Status : IND Enabling

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank

                          03

                          BioProcess International
                          Not Confirmed
                          BioProcess International
                          Not Confirmed

                          Details : LEM-S401 is a siRNA gene therapy drug that can treat and prevent hypertrophic scars, also claims to minimize the incidence of scars and the ability to remove pre-existing scars, increasing quality of lif...

                          Brand Name : LEM-S401

                          Molecule Type : Large molecule

                          Upfront Cash : Not Applicable

                          April 26, 2022

                          Lead Product(s) : LEM-S401

                          Therapeutic Area : Dermatology

                          Highest Development Status : IND Enabling

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank